Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2011-06-29 AGM Information
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce les résultats de son Assemblée générale mixte qui s’est tenue à Marseille, le 29 juin 2011.
AGM Information Classification · 99% confidence The document text is titled "ASSEMBLEE GÉNÉRALE MIXTE D'INNATE PHARMA DU 29 JUIN 2011 : TOUTES LES RESOLUTIONS PROPOSEES ONT FAIT L'OBJET D'UN VOTE CONFORME AUX RECOMMANDATIONS DU DIRECTOIRE DE LA SOCIETE" (Mixed General Meeting of Innate Pharma of June 29, 2011: All proposed resolutions were voted in accordance with the recommendations of the Management Board). It explicitly announces the results of the General Meeting, including quorum details and the renewal of Supervisory Board mandates. This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2011-06-29 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today the outcome of its Annual General Meeting (“AGM”) which took place on June 29, 2011, in Marseilles, France.
AGM Information Classification · 100% confidence The document is explicitly titled "INNATE PHARMA'S ANNUAL GENERAL MEETING OF JUNE 29, 2011: ALL PROPOSED RESOLUTIONS WERE VOTED ACCORDING TO MANAGEMENT'S RECOMMENDATIONS" and repeatedly refers to the "Annual General Meeting ("AGM")". It details the outcome of the votes on resolutions and subsequent board appointments. This directly aligns with the definition of AGM Information (AGM-R). It is not a full 10-K, an earnings release (ER), or a proxy statement (PSI), but rather the announcement of the results from the meeting itself.
2011-06-29 English
Innate Pharma (Euronext Paris : FR0010331421 – IPH) annonce la tenue de son assemblée générale annuelle le 29 juin 2011 à Marseille.
AGM Information Classification · 98% confidence The document is titled "INNATE PHARMA ANNONCE LA TENUE DE SON ASSEMBLÉE GÉNÉRALE ANNUELLE LE 29 JUIN 2011 A MARSEILLE" (Innate Pharma announces the holding of its Annual General Meeting on June 29, 2011, in Marseille). It details the date, location, agenda, voting procedures, and documentation availability for the upcoming Annual General Meeting (AGM). This content directly relates to the preparation and announcement of the AGM. Although it mentions the 'avis de réunion' (notice of meeting) and preparatory documents, the primary focus is the announcement of the meeting itself, which aligns best with the 'AGM Information' category (AGM-R). It is not the voting results (DVA) nor the proxy solicitation materials (PSI), but the announcement of the meeting itself.
2011-05-26 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders on June 29, 2011, in Marseilles, France.
AGM Information Classification · 98% confidence The document explicitly announces the date, time, and location for the 'Annual General Meeting of Shareholders ("AGM")'. It details instructions for participation, voting, and obtaining preparatory documentation related to this meeting. This content directly aligns with the definition of AGM Information, which is classified as 'AGM-R'. Although it mentions the publication of the 'Notice of Meeting', the primary focus is the event itself and the associated logistics, making AGM-R the most precise fit over RPA or RNS.
2011-05-26 English
Innate Pharma (Euronext Paris : FR0010331421 – IPH) annonce le renforcement de son équipe de direction avec la nomination de Catherine Moukheibir à son Directoire
Board/Management Information Classification · 99% confidence The document is a press release dated May 5, 2011, announcing the appointment of Catherine Moukheibir to the Management Board (Directoire) and as Senior Advisor Finance of Innate Pharma. This content directly relates to changes in the company's senior management team. According to the definitions, this falls under 'Board/Management Information' (Code: MANG). The document is not an annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2011-05-05 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today the reinforcement of its management with the appointment of Catherine Moukheibir to its Executive board
Board/Management Information Classification · 99% confidence The document is a press release dated May 5, 2011, announcing the appointment of Catherine Moukheibir to the Executive Board as Senior Advisor Finance. This content directly relates to changes in senior management personnel. Reviewing the definitions, the 'Board/Management Information' category (Code: MANG) is defined as 'Announcement of changes in the company's board of directors or senior management.' This perfectly matches the document's subject matter. It is not an earnings release, a capital change, or a general regulatory filing.
2011-05-05 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.